www.avibio.com
AVI BioPharma, Inc. is a biopharmaceutical company specializing in the discovery and development of ribonucleic acid based drugs targeting a range of diseases.
News
-
02/04/12
AVI BioPharma shares sink after phase 2 study results for eteplirsen -
08/09/10
AVI BioPharma Receives Patent For RNA-based Therapeutics
Recent Sector News
-

Dow seen opening higher ahead of jobless data, Facebook, Hewlett-Packard in focus
U.S. equity markets looked set to point to open higher Thursday after strong earnings from Hewlett-Packard (NYSE:HPQ), and as talks progress on Greece's debt crisis.
-

Dow suffers on Greece fears, Hewlett-Packard in focus
U.S. equity markets fell Wednesday afternoon on concerns that Greece could exit the euro as the region’s gather for an informal meeting.
-

Dow points lower ahead of eurozone meeting, Facebook, Dell in focus
U.S. equity markets looked set to open lower Wednesday morning ahead of a meeting of European Union leaders amid continued worries over the eurozone debt crisis.
-

Q1 gold demand underpinned by China, Central Banks and ETFs
Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
-

Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up
Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
-

Facebook boosts public offering by 25%
Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
What do others think of AVI BioPharma
Investors interested in AVI BioPharma recently viewed
-
Medgenics (AIM: MEDG) Developing "Biopump" technology for the treatment of chronic diseases -
OncoSec Medical Incorporated (OTCBB: ONCS) . -
Renovo Group Plc (LSE: RNVO) Renovo: Improving scar appearance and enhancing wound healing -
iSonea Limited (ASX: ISN) From Wheeze Identification to Wheeze Quantification -
Silence Therapeutics (AIM: SLN) A leader in RNAi therapeutics



















